TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata
TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata
TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn’s<br />
Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology<br />
2009;7:874–881<br />
103 Sarah Caspersen, Margarita Elkjaer, Lene Riis, Natalia Pedersen, et al.<br />
Infliximab for Inflammatory Bowel Disease in Denmark 1999–2005: Clinical<br />
Outcome and Follow-Up Evaluation of Malignancy and Mortality Clinical<br />
Gastroenterology and Hepatology 2008;6:1212–1217<br />
104 Penn I. Cancers complicating organ transplantation. N Engl J Med<br />
1990;323:1767.<br />
105 Corey A. SiegeL, Chin Hur, Joshua R. Korzenik,G.Scott Gazelle,and<br />
Bruce E. Sands Risks and Benefits of Infliximab for the Treatment of Crohn’s<br />
Disease Clinical Gastroenterology and Hepatology 2006;4:1017–1024<br />
106 via Biancone*, Emma Calabrese, Carmelina Petruzziello and Francesco<br />
Pallone<br />
Treatment with biologic therapies and the risk of cancer in patients with<br />
IBD.Nature Clinical Practice Gastroenterology & Hepatology 2007 VOL 4 N<br />
2<br />
107 Jean–Frederic Colombel, Edward V. Loftus, JR., and William J. Sandborn<br />
The Safety Profile of Infliximab in Patients With Crohn’s Disease: The Mayo<br />
Clinic Experience in 500 Patients.Gastroenterology 2004;126:19–31<br />
108 Paul Rutgeerts, Geert D’Haens, Stephan Targan, Eric Vasiliauskas et al.<br />
Efficacy and Safety of Retreatment With Anti–Tumor Necrosis Factor Antibody<br />
(Infliximab) to Maintain Remission in Crohn’s Disease, Gastroenterology<br />
1999;117:761–769<br />
83
Change language